Antimicrobial peptides towards clinical application: Delivery and formulation

Wang, Cheng; Hong, Tingting; Cui, Pengfei; Wang, Jianhao; Xia, Junfeng

doi:10.1016/j.addr.2021.05.028

Cited by 148 publications

(100 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Resistance to AMPs results from multiple nonspecific mechanisms such as secretion of proteases and activation of efflux pumps, but AMPs still demonstrate less probability of resistance evolution since they kill bacteria faster and interact with bacterial cell surface rather than directly mutagenic [ 59 , 60 ]. Along with the advances on drug delivery and formulation, AMPs hold great potential combat MDR [ 61 ]. Epinecidin-1 ( 53 , Figure 6 ) is a 20-amino-acid peptide produced by orange-spotted grouper Epinephelus coioides , playing an important role in protecting fish against Gram-positive and Gram-negative bacteria [ 62 ].…”

Section: Emerging Mnps As Promising Antibiotics For Inhibiting ...mentioning

confidence: 99%

Discovery of Marine Natural Products as Promising Antibiotics against Pseudomonas aeruginosa

Maimaitiming

Zhou

et al. 2022

Marine Drugs

View full text Add to dashboard Cite

Pseudomonas aeruginosa, one of the most intractable Gram-negative bacteria, has become a public health threat due to its outer polysaccharide layer, efflux transporter system, and high level of biofilm formation, all of which contribute to multi-drug resistance. Even though it is a pathogen of the highest concern, the status of the antibiotic development pipeline is unsatisfactory. In this review, we summarize marine natural products (MNPs) isolated from marine plants, animals, and microorganisms which possess unique structures and promising antibiotic activities against P. aeruginosa. In the last decade, nearly 80 such MNPs, ranging from polyketides to alkaloids, peptides, and terpenoids, have been discovered. Representative compounds exhibited impressive in vitro anti-P. aeruginosa activities with MIC values in the single-digit nanomolar range and in vivo efficacy in infectious mouse models. For some of the compounds, the preliminary structure-activity-relationship (SAR) and anti-bacterial mechanisms of selected compounds were introduced. Compounds that can disrupt biofilm formation or membrane integrity displayed potent inhibition of multi-resistant clinical P. aeruginosa isolates and could be considered as lead compounds for future development. Challenges on how to translate hits into useful candidates for clinical development are also proposed and discussed.

show abstract

Section: Emerging Mnps As Promising Antibiotics For Inhibiting ...mentioning

confidence: 99%

Discovery of Marine Natural Products as Promising Antibiotics against Pseudomonas aeruginosa

Maimaitiming

Zhou

et al. 2022

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…Second, the low resistance of BCPs to proteolytic cleavage is one of the aspects of peptides that has raises the most questions. It explains their short half-life and, therefore, low bioavailability in vivo [ 123 ], a limitation that avoid using peptides as pharmaceutical agents.…”

Section: Current Status and Future Directionsmentioning

confidence: 99%

Bioactive cationic peptides as potential agents for breast cancer treatment

2021

View full text Add to dashboard Cite

Breast cancer continues to affect millions of women worldwide, and the number of new cases dramatically increases every year. The physiological causes behind the disease are still not fully understood. One in every 100 cases can occur in men, and although the frequency is lower than among women, men tend to have a worse prognosis of the disease. Various therapeutic alternatives to combat the disease are available. These depend on the type and progress of the disease, and include chemotherapy, radiotherapy, surgery, and cancer immunotherapy. However, there are several well-reported side effects of these treatments that have a significant impact on life quality, and patients either relapse or are refractory to treatment. This makes it necessary to develop new therapeutic strategies. One promising initiative are bioactive peptides, which have emerged in recent years as a family of compounds with an enormous number of clinical applications due to their broad spectrum of activity. They are widely distributed in several organisms as part of their immune system. The antitumoral activity of these peptides lies in a nonspecific mechanism of action associated with their interaction with cancer cell membranes, inducing, through several routes, bilayer destabilization and cell death. This review provides an overview of the literature on the evaluation of cationic peptides as potential agents against breast cancer under different study phases. First, physicochemical characteristics such as the primary structure and charge are presented. Secondly, information about dosage, the experimental model used, and the mechanism of action proposed for the peptides are discussed.

show abstract

“…Antimicrobial peptides (AMPs) are also a powerful weapon against multidrug resistance in the “post-antibiotic era”. 23–26 Their unique mechanism of membrane destruction often makes them broad-spectrum antimicrobials, and as the membrane is so essential for bacterial cells, resistance development will be relatively rare. Therefore, we speculate that the combination of low temperature photothermal and photodynamic therapy with antimicrobial peptides may achieve an added effect of “1 + 1 > 2”, that is the former reduces the viability of bacterial cells and opens a gap in the biofilm, while the latter carries out physical infiltration for the final effective harvest.…”

Section: Introductionmentioning

confidence: 99%